Product Description
| Cat Number | SPR-452E |
|---|---|
| Category | Recombinant Protein |
| Pack Size | 100 µg x5 |
| Description | Human Recombinant Transthyretin Y78F Variant Protein Monomers |
| Applications | WB | SDS-PAGE | In vivo assay | In vitro assay |
| Target | Transthyretin (TTR) |
| Molecular Weight | 13.876 kDa |
| Cellular Localization | Cytoplasm | Extracellular exosome | Extracellular Region | Lysosome |
| Purity | >95% |
| Research Area | Neuroscience | Neurodegeneration | Alzheimer's Disease | ALS Disease | Tangles & Tau | Parkinson's Disease | Cardiovascular System | Blood | Cell Signaling | Metabolism | Lipid and lipoprotein Metabolism |
| Swiss Prot | P02766 |
| Scientific Background | Transthyretin is a transport protein in the serum and cerebospinal fluid that carried the thyroid hormone Thyroxine and retinol-binding protein bound to retinol. TTR misfolding and aggregation is known to be associated with the amyloiddiseases SSA, FAP and FAC (1-5). TTR is also thought to have beneficial side effects, such as binding to beta-amyloid protein, preventing beta-amyloid from accumulating into the plaques associated with Alzheimer's Disease (6). The mutant variant Y78F indicates a destabilization of the contacts between the alpha-helix and AB loop and the body of the molecule, potentially leading to applications in immne therapy for FAP (7). |
| Expression System | E. coli |
| Accession Number | NP_000362.1 |
| Gene Id | 7276 |
| Protein Length | Full length |
| Amino Acid Sequence | MGPTGTGESKCPLMVKVLDAVRGSPAINVAVHVFRKAADDTWEPFASGKTSESGELHGLTTEEEFVEGIYKVEIDTKSFWKALGISPFHEHAEVVFTANDSGPRRYTIAALLSPYSYSTTAVVTNPKE |
| Purification | Ion-exchange Purified |
| Storage | -80ºC |
| References | 1. Zeldenrust S.R., Benson M.D. (2010). Wiley. pp. 795–815. 2. Westermark P., Sletten K., Johansson B., Cornwell G.G. (1990). Proc. Natl. Acad. Sci. U.S.A. 87(7): 2843–5. 3. Andrade C. (1952). Brain. 75(3): 408–27. 4. Coelho T. (1996). Curr. Opin. Neurol. 9(5): 355–9. 5. Jacobson D.R, et. al. (1997). N. Engl. J. Med. 336(7): 466–73. 6. Li X. (2011). Mol Neurodegener. 6(1):79. 7. Terazaki H.,m et al. (2006) Lab Invest. 86(1): 23-31. |
| Product Url | View Document |
| Note | The product is for research use only |
Share Item: